Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9BU64
UPID:
CENPO_HUMAN
Alternative names:
Interphase centromere complex protein 36
Alternative UPACC:
Q9BU64; B2RDC0; D6W536; Q53T55; Q96JV3
Background:
Centromere protein O, also known as Interphase centromere complex protein 36, plays a crucial role in chromosome segregation during cell division. It is a component of the CENPA-CAD complex, essential for the assembly of kinetore proteins, mitotic progression, and chromosome segregation. This protein is key in incorporating newly synthesized CENPA into centromeres, interacting with the CENPA-NAC complex and modulating the kinetochore-bound levels of the NDC80 complex.
Therapeutic significance:
Understanding the role of Centromere protein O could open doors to potential therapeutic strategies.